Synthesis of structurally complex and highly-engineered protein sequences to enable acceptance of approximately 99.5% of clonal gene orders and 99.9% of all DNA products

Complex synthesis capabilities to support further advancement of AI-enabled drug discovery and nucleic acid therapeutics

Twist Bioscience Corporation (NASDAQ:TWST), a mid-cap growth and value biotech company, today expanded its clonal genes portfolio with the early access launch of Complex Genes.